




RealRate

# PHARMACEUTICAL 2018

Nabriva Therapeutics plc  
Rank 259 of 349



RealRate

• Financial Strength Rankings using Artificial Intelligence

• [www.realrate.ai](http://www.realrate.ai)

The relative strengths and weaknesses of Nabriva Therapeutics plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nabriva Therapeutics plc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 166% points. The greatest weakness of Nabriva Therapeutics plc is the variable Net Income, reducing the Economic Capital Ratio by 209% points.

The company's Economic Capital Ratio, given in the ranking table, is -387%, being 109% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	93,839
Cost of Goods Sold	0
Intangible Assets	172
Liabilities, Current	13,260
Liabilities, Non-Current	435
Other Assets	425
Other Compr. Net Income	17
Other Expenses	1,398
Other Liabilities	0
Other Net Income	6,129
Property and Equipment	1,327
Research and Development	49,615
Revenues	0
Selling, General and Administrative Expense	29,472

Output Variable	Value in 1000 USD
Assets	95,763
Liabilities	13,695
Expenses	80,485
Stockholders Equity	82,068
Net Income	-74,356
Comprehensive Net Income	-74,348
Economic Capital Ratio	-387%